Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,656 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Terminated Phase 1 Interventional

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

NCT01948297
View directory record Official record
Conditions
Solid Tumours
Interventions
Debio1347 (CH5183284)
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 25, 2026, 11:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Placental Growth and Adverse Pregnancy Outcomes

NCT01669525
View directory record Official record
Conditions
Hypertension Induced by Pregnancy, Pre-Eclampsia, IUGR
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Female only
Enrollment
1,043 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nutritional and Contractile Regulation of Muscle Growth

NCT00891696
View directory record Official record
Conditions
Sarcopenia
Interventions
Rapamycin, Amino acid supplementation, Low-intensity resistance exercise, Sodium nitroprusside, Blood flow restriction cuff
Drug · Other · Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 25, 2026, 11:56 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Families Filming Infants Learning Movement

NCT06278961
View directory record Official record
Conditions
Infant Development, Cerebral Palsy, Motor Disorders, Neurological Disorder
Interventions
Observational
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Weeks to 20 Weeks
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 11:56 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

NCT05514496
View directory record Official record
Conditions
EGFR Mutation-Related Tumors
Interventions
NX-019
Drug
Lead sponsor
Nalo Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Duarte, California • Huntington Beach, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT00509769
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab emtansine [Kadcyla]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2013 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

NCT01664182
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, Sunitinib Malate, Trebananib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 25, 2026, 11:56 PM EDT
Recruiting Not applicable Interventional

Maternal Left Lateral Position in Fetal Growth Restriction

NCT06919692
View directory record Official record
Conditions
Fetal Growth Restriction
Interventions
Left lateral recumbent positioning
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Muscle Growth Following a Resistance Training Program in Men and Women Consuming Protein Supplements

NCT03868631
View directory record Official record
Conditions
Skeletal Muscle Growth
Interventions
Whey protein supplement, Soy protein supplement
Dietary Supplement
Lead sponsor
Point Loma Nazarene University
Other
Eligibility
18 Years to 35 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects on Growth and Tolerance of an Infant Formula Fed to Term Infants

NCT01897922
View directory record Official record
Conditions
Growth of Term Infants
Interventions
An investigational infant formula containing a probiotic source, Control: Marketed routine infant formula
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
12 Days to 16 Days
Enrollment
348 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 25, 2026, 11:56 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness

NCT01686295
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
iRestore Hair Rejuvenation System, sham device
Device
Lead sponsor
Freedom Laser Therapy, Inc.
Industry
Eligibility
25 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis Of The Hip

NCT00744471
View directory record Official record
Conditions
Arthritis, Osteoarthritis, Osteoarthritis, Hip
Interventions
tanezumab, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
99
States / cities
Mobile, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 25, 2026, 11:56 PM EDT
Completed No phase listed Observational Results available

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 25, 2026, 11:56 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Fetal Genome Profiling Via Trophoblast Cells

NCT03832634
View directory record Official record
Conditions
Fetal Growth Retardation
Interventions
Fetal Genome Profiling.
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 25, 2026, 11:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552
View directory record Official record
Conditions
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma, Solid Tumor, Adult, Bladder Cancer, Non-muscle-invasive Bladder Cancer, FGFR3 Gene Mutation, FGFR3 Gene Alteration, Advanced Solid Tumor, Advanced Urothelial Carcinoma, Urinary Tract Cancer, Urinary Tract Tumor, Urinary Tract Carcinoma
Interventions
TYRA-300
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 25, 2026, 11:56 PM EDT
Terminated Not applicable Interventional Results available

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

NCT00145704
View directory record Official record
Conditions
Osteopenia
Interventions
bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium
Drug · Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 25, 2026, 11:56 PM EDT
Terminated Not applicable Interventional Results available

CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies

NCT01440452
View directory record Official record
Conditions
Inflammatory Myelopathies
Interventions
FES Cycling, Cycling without FES, Lumbar puncture, Mood assessment
Device · Procedure · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 25, 2026, 11:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ontogeny of Measles Immunity in Infants

NCT00240916
View directory record Official record
Conditions
Measles
Interventions
Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous), MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2013
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

NCT02272998
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
ponatinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

NCT02712008
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
REGN910-3, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
51
States / cities
Mesa, Arizona • Tucson, Arizona • Arcadia, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

NCT01441947
View directory record Official record
Conditions
Breast Cancer
Interventions
Cabozantinib, Fulvestrant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 25, 2026, 11:56 PM EDT
Terminated Phase 4 Interventional Results available

Body Composition and Adipose Tissue in HIV

NCT03226821
View directory record Official record
Conditions
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
Interventions
Tesamorelin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 68 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 25, 2026, 11:56 PM EDT
Active, not recruiting Phase 2 Interventional

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

NCT00044304
View directory record Official record
Conditions
Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome
Interventions
Imatinib, Ruxolitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 25, 2026, 11:56 PM EDT
Completed Phase 2 Interventional

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

NCT03967249
View directory record Official record
Conditions
Acromegaly
Interventions
IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL)
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Birmingham, Alabama • Evanston, Illinois • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 25, 2026, 11:56 PM EDT